The chloroquinoline scaffold is characteristic of anti-malarial drugs such as chloroquine (CQ) or amodiaquine (AQ). These drugs are also described for their potential effectiveness against prion disease, HCV, EBV, Ebola virus, cancer, Parkinson or Alzheimer diseases. Amyloid precursor protein (APP) metabolism is deregulated in Alzheimer’s disease. Indeed, CQ modifies amyloid precursor protein (APP) metabolism by precluding the release of amyloid-beta peptides (Aβ), which accumulate in the brain of Alzheimer patients to form the so-called amyloid plaques. We showed that AQ and analogs have similar effects although having a higher cytotoxicity. Herein, two new series of compounds were synthesized by replacing 7-chloroquinolin-4-amine moiety of AQ by 2-aminomethylaniline and 2-aminomethylphenyle moieties. Their structure activity relationship was based on their ability to modulate APP metabolism, Aβ release, and their cytotoxicity similarly to CQ. Two compounds 15a, 16a showed interesting and potent effect on the redirection of APP metabolism toward a decrease of Aβ peptide release (in the same range compared to AQ), and a 3–10-fold increased stability of APP carboxy terminal fragments (CTFα and AICD) without obvious cellular toxicity at 100 µM.

氯喹啉支架是抗疟疾药物的特征，例如氯喹（CQ）或阿莫二喹（AQ）。还描述了这些药物对against病毒病，HCV，EBV，埃博拉病毒，癌症，帕金森氏症或阿尔茨海默氏病的潜在效力。淀粉样前体蛋白（APP）的代谢在阿尔茨海默氏病中被放松调节。实际上，CQ通过阻止淀粉样蛋白β肽（Aβ）的释放来修饰淀粉样蛋白前体蛋白（APP）的代谢，该蛋白积聚在阿尔茨海默病患者的大脑中，形成所谓的淀粉样蛋白斑。我们显示，尽管AQ和类似物具有更高的细胞毒性，但它们具有相似的作用。在此，通过用2-氨基甲基苯胺和2-氨基甲基苯基取代AQ的7-氯喹啉-4-胺部分，合成了两个新的系列化合物。它们的结构活性关系基于它们调节APP代谢，Aβ释放的能力以及类似于CQ的细胞毒性。两种化合物图15a，16a显示了对APP代谢的重新导向，即减少Aβ肽释放（与AQ处于同一范围内），并且APP羧基末端片段（CTFα和AICD）的稳定性提高了3-10倍，产生了有趣而有效的作用100 µM无明显细胞毒性。